Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Shanghai Commercial Bank Advances Governance, Risk, and Compliance Capabilities with Wolters Kluwer
Supporting the Bank’s digital transformation by enhancing Basel compliance, regulatory reporting, and…
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for…
![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](https://i0.wp.com/ml-eu.globenewswire.com/media/ZTQzNjcwMWUtZTZmZi00MTQ2LTk4YzEtMDM3YWJiOTVmYTcxLTEwMTQyODItMjAyNS0wNC0xNC1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US")
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its…
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples…
THE PENINSULA’S GLOBAL “ART IN RESONANCE” PROGRAMME 2025 SHOWCASES GROUNDBREAKING CONTEMPORARY ARTWORKS
Three commissioned artworks — including one in partnership with the Victoria and…
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…